Enhanced Recovery in Acute Pancreatitis
Enhanced Recovery in Acute Pancreatitis
Prospective randomized-controlled trial evaluating impact of enhanced recovery protocol
 compared to standard care for recovery of patients with acute pancreatitis.
Inclusion Criteria:

 -  Acute pancreatitis confirmed by clinical history, serologic testing and/or
 radiographic imaging

 Exclusion Criteria:

 -  • Severe acute pancreatitis defined as the presence of any of the following:

 -  Organ failure (oxygen saturation<90% on room air, mean arterial pressure<70 mmHG
 or any requirement for vasopressor or inotropic support, serum creatinine>2.0,
 Glasgow coma score<15)

 -  Suspected or confirmed infected pancreatic necrosis: fever, leukocytosis in the
 setting of suspicious findings on cross-sectional imaging (gas within necrotic
 collection) or confirmed infection on fine needle aspirate

 -  Chronic pancreatitis or any chronic pain syndrome requiring use of narcotic
 analgesic within 30 days prior to hospitalization

 -  Abdominal surgery within 60 days prior to hospitalization

 -  History of gastrointestinal motility disorder

 -  Inflammatory bowel disease

 -  Chronic comorbid illness including but not limited to >New York Heart
 Association Class II congestive heart failure, cirrhosis, oxygen-dependent
 chronic obstructive pulmonary disease or malignancy other than non-squamous
 skin cancer not in remission.

 -  Documented allegy to any of the following medications: dilaudid, Tylenol

 -  Patients transferred from an outside hospital for ongoing care

 -  Non-English speaking patients for whom an appropriate language interpretor
 cannot be identified.

 -  Pregnant women will be excluded from participation in this phase IIb trial
 given the limited projected sample size and rarity of this condition during
 pregnancy.

 -  Minors (patients <18 years of age) will not be eligible for study inclusion.
 The interventions being compared in the study protocol are standard care for
 adult patients with acute pancreatitis. However, the safety and efficacy of
 these treatments in the pediatric population has not been established.